HomeRGLS • NASDAQ
add
Regulus Therapeutics Inc
Previous close
$7.85
Day range
$7.84 - $7.88
Year range
$0.83 - $8.20
Market cap
544.87M USD
Avg Volume
2.28M
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
In the news
Financials
Income Statement
Revenue
Net income
| (USD) | Mar 2025info | Y/Y change |
|---|---|---|
Revenue | — | — |
Operating expense | 3.72M | 33.49% |
Net income | -9.63M | -13.76% |
Net profit margin | — | — |
Earnings per share | -0.15 | 48.28% |
EBITDA | -10.45M | -19.53% |
Effective tax rate | — | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Mar 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 65.37M | -32.99% |
Total assets | 74.83M | -34.44% |
Total liabilities | 5.80M | -11.48% |
Total equity | 69.03M | — |
Shares outstanding | 69.23M | — |
Price to book | 7.55 | — |
Return on assets | -33.14% | — |
Return on capital | -35.63% | — |
Cash Flow
Net change in cash
| (USD) | Mar 2025info | Y/Y change |
|---|---|---|
Net income | -9.63M | -13.76% |
Cash from operations | -10.61M | -21.40% |
Cash from investing | 21.50M | 127.37% |
Cash from financing | 45.00K | -99.95% |
Net change in cash | 10.93M | 87.87% |
Free cash flow | -6.34M | -1.31% |
About
Regulus Therapeutics Inc. is a clinical stage biopharmaceutical company focused on the development of first-in-class drugs that target microRNAs to treat a broad range of diseases. Regulus was established in September 2007 by Alnylam Pharmaceuticals and Isis Pharmaceuticals. Wikipedia
Founded
Sep 2007
Website
Employees
34
